FDA has released draft guidance addressing electronic submission templates for Investigational Device Exemption (IDE) applications submitted to its device and biologics centers, CDRH and CBER. The proposal is intended to improve submission consistency and support a more efficient review process. [1]
For manufacturers planning U.S. clinical investigations, this is a useful opportunity to review how regulatory, engineering, and clinical teams prepare their submission packages.
The guidance remains a draft, not for implementation. FDA is accepting comments through December 28, 2026. [1]
What is an IDE?
An Investigational Device Exemption allows an investigational medical device to be used in a clinical study to collect safety and effectiveness data. Investigational use can also involve certain modifications or new intended uses of devices already legally marketed. [3]
The study’s regulatory status matters. Significant-risk device studies require FDA IDE approval and institutional review board (IRB) approval before initiation. Not every device study requires an IDE application to FDA; sponsors need to assess whether their investigation is significant risk, nonsignificant risk, or exempt. An IDE supports investigational use; it does not provide commercial marketing authorization. [3] [5]
What is FDA proposing?
The draft, dated October 28, 2026, describes electronic-format standards for IDE applications and identifies eSTAR as the currently available submission template. Its scope includes original IDE applications, supplements, and amendments, subject to specified exemptions. [2]
FDA proposes exemptions for certain submissions, including IDE reports and related amendments, interactive review responses, appeals, and withdrawal requests. Sponsors should check the treatment of their particular submission type. [2]
The draft also distinguishes a conventional electronic copy, or eCopy, from an electronic submission prepared using a structured template. [2]
How does eSTAR help?
eSTAR—electronic Submission Template and Resource—is an interactive PDF that guides users through submission preparation. Its standardized structure helps applicants organize information and aligns with FDA’s review approach. [4]
FDA currently lists IDE submissions to CDRH and CBER as eligible for voluntary eSTAR use. Its Early Submission Requests template, known as PreSTAR, supports IDEs alongside specified other submission types. Sponsors should obtain the applicable current template and instructions directly from FDA. [4]
From a preparation standpoint, teams should treat the template as a way to organize their evidence. Technical questions, inconsistent document versions, and unresolved study assumptions still need substantive review.
When would the requirement take effect?
FDA proposes a transition period of at least one year after issuance of final guidance before requiring covered IDE applications to use the specified electronic submission format. This proposal does not establish an October 2026 implementation deadline. [2]
Although the document is currently a draft, specified electronic-format provisions would have binding effect when finalized under FDA’s statutory authority. Describing the future framework simply as optional guidance would therefore be incomplete. [2]
Five preparation steps for sponsors
AVRA recommends using this development as a planning opportunity:
- Confirm the study pathway. Document the investigation’s regulatory status before choosing a submission workflow.
- Build a document map. Connect each relevant template section to its supporting evidence, responsible owner, and approved document version.
- Check consistency across functions. Compare the device description, study protocol, labeling, and technical reports. Resolve discrepancies before assembling the final package.
- Run an internal preparation exercise. Have regulatory, engineering, and clinical colleagues work through the applicable template together and record missing information or unclear responsibilities.
- Assign someone to monitor the final guidance. Update submission procedures and project schedules when FDA confirms the final scope and implementation timetable.
These are AVRA’s preparation recommendations, not additional requirements imposed by the draft. The practical objective is a submission package that tells a consistent, evidence-supported story about the device and the proposed investigation.
Discuss your regulatory readiness with AVRA
AVRA Medical Consulting supports medical-device manufacturers with regulatory readiness, technical-documentation reviews, risk-management documentation, and U.S. and Brazil market-access planning.
To discuss your project and the support it needs, contact contact@avramed.us.